Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	2.51T
Revenue (ttm)	1.29T
Net Income (ttm)	52.75B
Shares Out	67.71M
EPS (ttm)	778.50
PE Ratio	47.59
Forward PE	n/a
Dividend	400.00 (1.08%)
Ex-Dividend Date	Jun 27, 2025

Volume	504,813
Average Volume	280,106
Open	34,700
Previous Close	35,300
Day's Range	33,900 - 37,750
52-Week Range	24,250 - 52,500
Beta	0.96
RSI	70.62
Earnings Date	Jul 25, 2025

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 444
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2024, Hanmi Science's revenue was 1.28 trillion, an increase of 2.85% compared to the previous year's 1.25 trillion. Earnings were 59.42 billion, a decrease of -48.38%.